CHEETAH MEDICAL ANNOUNCES RESULTS OF KEY SEPSIS STUDY
March, 2017. NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical, a rapidly growing medical device company, announced the results of a major new study conducted by Drs. Heath Latham and Steven Q. Simpson from the University of Kansas Medical Center. The study was designed to evaluate fluid resuscitation in ICU patients with severe sepsis and septic shock, and results were presented this week at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) Congress in Brussels.
The study compared the volume of fluid administered and associated patient outcomes between two groups of patients with severe sepsis or septic shock in the ICU:
- A test group where fluid resuscitation was guided by stroke volume (SV) using Cheetah Medical’s noninvasive hemodynamic monitoring system (CHEETAH NICOM™). The Cheetah system provides clinicians with the ability to determine whether their patient will be able to respond to additional fluids by increasing cardiac output and perfusion.
- A usual care group in which patients were treated at the discretion of the healthcare providers.
Results show that patients who received treatment guided by Cheetah’s hemodynamic system exhibited a significantly decreased fluid balance at the end of their ICU stay (1.77 + 0.6 L) compared to the usual care group (5.36 +1.01 L, p=0.002). Excess fluid can result in costly complications such as mechanical ventilation and added days in the ICU and hospital.
Notably, ICU length of stay, vasopressor use, and the need for mechanical ventilation were all reduced in the test group:
- Patients in the test group exhibited a decreased ICU length of stay by 2.9 days (5.98 + 0.68 days) compared to usual care (8.87 + 1.18 days; p=0.03)
- Patients in the test group were less likely to require mechanical ventilation (Relative Risk 0.51)
- Patients in the test group required significantly less time on vasopressor therapy (32.08 + 5.22 hours) compared to the usual care group (64.86 + 8.39 hours; p=0.001)
Dr. Steven Q. Simpson, Acting Director, Division of Pulmonary Disease and Critical Care Medicine at the University of Kansas Medical Center commented: “These finding underscore the importance of stroke volume guided fluid management in the high risk severe sepsis and septic shock patient population. By reducing length of stay, vasopressor use, and the requirement for mechanical ventilation using dynamic assessments provided by the Cheetah Medical system, sepsis patients may benefit by an improved quality of care and reduced healthcare costs.”
The CHEETAH NICOM and STARLING SV hemodynamic monitoring systems provide the ability to obtain 100% noninvasive dynamic assessments of fluid responsiveness to guide volume management in critical care, operating room and emergency department settings.
“We’ve known that using dynamic measures improve outcomes in surgical patients. Now, it is exciting to see a building level of evidence that stroke volume guided fluid management may bring meaningful patient improvements in severe sepsis and septic shock,” said Dr. Douglas Hansell, Chief Medical Officer at Cheetah Medical.
About Cheetah Medical
Cheetah Medical is the pioneer and leading global provider of 100% noninvasive hemodynamic monitoring technologies that are designed for use in critical care, OR and emergency department settings. The CHEETAH NICOM™ and STARLING™ SV technologies use a proprietary algorithm to calculate parameters related to the volume of blood and the functioning of patients’ circulatory systems. Medical professionals use this information to assess patients’ unique volume requirements, guide volume management decisions and maintain adequate organ perfusion. Cheetah Medical technologies are designed to enable more confident, informed therapy decisions that support clinical goals of improving patient outcomes and driving economic efficiencies.
Shane Cooke, 617-964-0613
Could HighCape be the right partner for your growing business?
Contact us for more information.
452 5th Ave, 21st Floor
New York, NY 10018